Ultragenyx Pharmaceutical Inc. (RARE) Financials
Key financial figures for Ultragenyx Pharmaceutical Inc. (Q2 2026).
Ultragenyx Pharmaceutical Inc. reported revenue of $214.0 million for Q2 FY2026, up 28.5% from the same period a year earlier. The company posted a net loss of $92.0 million, or -$0.90 per share. Operating margin came to -35.05%, against -64.8% a year earlier. Free cash flow for the period was -$98.0 million. Across the last 5 reported quarters, quarterly revenue has risen from $166.5 million in Q2 FY2025 to $214.0 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Ultragenyx Pharmaceutical Inc. are on the SentiSense financials page.
- Revenue
- $214M
- Net Income
- -$92M
- EPS
- $-0.90
- Total Assets
- $1.3B
- Operating Cash Flow
- -$97M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $214M | -$92M | -$0.90 | -35.05% | -$98M |
| Q1 FY2026 | $136M | -$185M | -$1.84 | -124.26% | -$198M |
| Q4 FY2025 | $207M | -$129M | -$1.29 | -55.07% | -$101M |
| Q3 FY2025 | $160M | -$180M | -$1.81 | -106.85% | -$93M |
| Q2 FY2025 | $166M | -$115M | -$1.17 | -64.8% |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $673M | -$575M | -$5.83 | -79.49% | -$472M |
| FY2024 | $560M | -$569M | -$6.29 | -95.67% | -$422M |
| FY2023 | $434M | -$607M | -$8.25 | -131.08% | -$522M |
Frequently asked questions
What was Ultragenyx Pharmaceutical Inc.'s revenue last quarter?
Ultragenyx Pharmaceutical Inc. reported revenue of $214.0 million for Q2 FY2026, up 28.5% from the same period a year earlier.
Is Ultragenyx Pharmaceutical Inc. profitable?
Not in its most recent reported period. Ultragenyx Pharmaceutical Inc. reported a net loss of $92.0 million for Q2 FY2026, a net margin of -42.99% on revenue.
How has Ultragenyx Pharmaceutical Inc.'s margin trended?
Operating margin was -35.05% in Q2 FY2026, compared with -64.8% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Ultragenyx Pharmaceutical Inc. generate?
Ultragenyx Pharmaceutical Inc. generated free cash flow of -$98.0 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Ultragenyx Pharmaceutical Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.